Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation..     ///    One patient with metastatic myxoid liposarcoma with TLS-CHOP translocation had a durable response and received 40?cycles of amrubicin. 